Granza Bio is dedicated to developing cancer therapeutics modeled after the body's immune system. Their "attack particles" are engineered to specifically target cancer cells, minimizing toxicity and adverse effects. These therapeutics have shown efficacy in treating brain, ovarian, lung, and skin cancers and have potential applications in autoimmune diseases and infections.

Granza Bio has demonstrated significant progress in cancer treatment, with notable affiliations including Y Combinator and the University of Oxford. Their innovative approach has positioned them as a promising player in the biotech industry, aiming to revolutionize cancer therapy and beyond.